Deutsche Bank Ag\ Aligos Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.04 - $2.14 $12,218 - $25,142	-11,749 Reduced 14.15%	71,290 $86,000
Q1 2022 May 13, 2022	SELL	$2.08 - $12.2 $2,824 - $16,567	-1,358 Reduced 1.61%	83,039 $179,000
Q4 2021 Feb 11, 2022	BUY	$11.48 - $17.69 $7,404 - $11,410	645 Added 0.77%	84,397 $1 Million
Q3 2021 Nov 04, 2021	SELL	$14.57 - $17.72 $185,607 - $225,735	-12,739 Reduced 13.2%	83,752 $1.3 Million
Q2 2021 Aug 11, 2021	BUY	$20.3 - $33.6 $121,414 - $200,961	5,981 Added 6.61%	96,491 $1.97 Million
Q1 2021 May 13, 2021	BUY	$19.1 - $34.94 $1.59 Million - $2.91 Million	83,427 Added 1177.85%	90,510 $2.06 Million
Q4 2020 Feb 16, 2021	BUY	$13.2 - $32.74 $93,495 - $231,897	7,083 New	7,083 $196,000

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.3B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.